InMed Pharmaceuticals Inc. (NASDAQ: INM) (‘InMed’ or the ‘Company’), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC (‘BayMedica’), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal…
A new US-Venezuela gold deal could soon channel hundreds of kilograms of bullion from the South American nation into…
Nuvau Minerals Inc. (TSXV: NMC,OTC:NMCPF) (the ‘Company’ or ‘Nuvau’) is pleased to announce that it has closed the second…
Peter Krauth, editor of Silver Stock Investor and Silver Advisor, shares his thoughts on silver price activity and where…
The Government of New Brunswick announced a new comprehensive mineral strategy on Tuesday (March 3), at the 2026 Prospectors…
Adrian Day, president of Adrian Day Asset Management, shares his latest thoughts on what’s moving the gold price, emphasizing…
Brien Lundin, editor of Gold Newsletter and New Orleans Investment Conference host, shares his stock-picking strategy at a time…
/Not for distribution to United States newswire services or for dissemination in the United States/ Lithium Africa Corp. (TSXV:…